Brief: Ascletis Announces Completion Of 180 Patient Enrollment For Phase Ii Clinical Trial Of Fasn Inhibitor Asc40 For Acne
30/11/2022 12:40
Nov 30 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ASCLETIS ANNOUNCES COMPLETION OF 180 PATIENT ENROLLMENT
FOR
PHASE II CLINICAL TRIAL OF FASN INHIBITOR ASC40 FOR ACNE
Source text for Eikon: ID:nPn7cyNk0a
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026